Patents by Inventor Michael G. Schlossmacher

Michael G. Schlossmacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for identifying &bgr;-amyloid peptide production inhibitors
    Patent number: 6284221
    Abstract: A method for identifying inhibitors of the production of &bgr;-amyloid peptides by administration of a compound to a mammalian host is provided.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: September 4, 2001
    Assignees: Elan Pharmaceuticals, Inc., Eli Lilly and Company, Brigham and Women's Hospital, Inc.
    Inventors: Dale B. Schenk, Michael G. Schlossmacher, Dennis J. Selkoe, Peter A. Seubert, Carmen Vigo-Pelfrey
  • Methods and compositions for the detection of soluble .beta.-amyloid peptide
    Patent number: 5837672
    Abstract: Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: November 17, 1998
    Assignees: Athena Neurosciences, Inc., Eli Lilly and Company, Brigham and Women's Hospital
    Inventors: Dale B. Schenk, Michael G. Schlossmacher, Dennis J. Selkoe, Peter A. Seubert, Carmen Vigo-Pelfrey
  • Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production
    Patent number: 5766846
    Abstract: Soluble .beta.-amyloid peptide (.beta.AP) is measured in biological fluids at very low concentrations, typically in the range from 0.1 ng/ml to 10 ng/ml. The measurement of .beta.AP concentrations in animals or conditioned medium from cultured cells can be used for drug screening, where test compounds are administered to the animals or exposed to the cultured cells and the accumulation of .beta.AP in the animal or culture medium observed. It has been found that elevated levels of .beta.AP in body fluids, such as blood and cerebrospinal fluid, is associated with the presence of a .beta.AP-related condition in a patient, such as Alzheimer's Disease. Methods for diagnosing and monitoring .beta.AP-related conditions comprise measuring the levels of .beta.AP in such body fluids from a patient.
    Type: Grant
    Filed: June 17, 1993
    Date of Patent: June 16, 1998
    Assignees: Athena Neurosciences, Eli Lilly and Company
    Inventors: Michael G. Schlossmacher, Dennis J. Selkoe